Диссертация (1174244), страница 20
Текст из файла (страница 20)
Aranami, S. Miyake, T.Yamamura // J Immunol. – 2006. – Vol. 177. – P. 5659-5667.13090. Belbasis, L. Environmental risk factors and multiple sclerosis: an umbrellareview of systematic reviews and meta-analyses. / L. Belbasis, V. Bellou, E. Evangelouet al. // Lancet Neurol. – 2015. – Vol. 14. – P. 263–273.91. Blewett, M.M. Lipid autoreactivity in multiple sclerosis / M.M. Blewett //Med hypotheses.
– 2010. – Vol. 74, № 3. – P.433–442.92. Bsteh, G. Long Term Clinical Prognostic Factors in Relapsing-RemittingMultiple Sclerosis: Insights from a 10-Year Observational Study / G. Bsteh, R. Ehling,A. Lutterotti et al. // PLOS One. – 2016. – Vol. 11, №1. – P. 1-14.93. Chen, D. CD40-Mediated NF-kB Activation in B Cells Is Increased inMultiple Sclerosis and Modulated by Therapeutics / D. Chen, S.J.
Ireland, G.Remington et. al. // J Immunol. – 2016. – Vol. 197, №11. – P. 4257-4265.94. Comabella, M. Body fluid biomarkers in multiple sclerosis / M. Comabella,X. Montalban // The Lancet Neurology. – 2014. – Vol. 13, № 1. – P. 113–126.95. Cree, B.A.C. Current therapeutic landscape in multiple sclerosis: anevolving treatment paradigm / B.A.C. Cree, J. Mares, H.-P. Hartung // Current Opinionin Neurology. – 2019. – Vol. 32, № 3.
– P. 365–377.96. Cusick, M.F. Multiple sclerosis: autoimmunity and viruses / M.F. Cusick,J.E. Libbey, R.S. Fujinami // Current Opinion in Rheumatology. - 2013 – Vol. 25, № 4.– P. 496–501.97. Dendrou, C.A. Immunopathology of multiple sclerosis / C.A. Dendrou, L.Fugger, M.A.
Friese // Nature Reviews Immunology. – 2015. – Vol. 15. – P. 545-558.98. Einstein, O. Neural Precursors Attenuate Autoimmune Encephalomyelitis byPeripheral Immunosuppression / O. Einstein, N. Fainstein, I. Vaknin et al. // Annals ofNeurology. – 2007. – Vol. 61, № 3. – P. 209–218.99. Franklin, R. The biology of CNS remyelinisation / R. Franklin, M. Kotter //J neurol.
– 2008. – Vol. 255, № 1. – P. 19–25.100. Fransson, M.E. The T-cell pool is anergized in patients with multiplesclerosis in remission / M.E. Fransson, L.S.E. Liljenfeldt, J. Fagius et al. //Immunology. – 2008. – Vol. 126. – P. 92–101.131101. Freedman, М.S. Severe, Highly Active, or Aggressive Multiple Sclerosis /M.S.
Freedman, C.A. Rush // Continuum – 2016. – Vol. 22, № 3. – P. 761–784.102. Frischer, J.M. The relation between inflammation and neurodegeneration inmultiple sclerosis brains / J.M. Frischer, S. Bramow, A. Dal-Bianco et al. // Brain: AJournal of Neurology. – 2009. – Vol.
132. – P. 1175–1189.103. Harris, V.K. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derivedNeural Progenitors in Progressive Multiple Sclerosis / V.K. Harris, J. Stark, T.Vyshkina et al. // EBioMedicine. – 2018. – Vol. 29. – P. 23-30.104. Hemmer, B. Role of the innate and adaptive immune responses in the courseof multiple sclerosis / B. Hemmer, M. Kerschensteiner, T. Korn // Lancet Neurol.
–2015. - Vol. 14. – P. 406–419.105. Hernández-Pedro, N.Y. Initial Immunopathogenesis of Multiple Sclerosis:Innate Immune Response / N.Y. Hernández-Pedro, G. Espinosa-Ramirez, V.P. de laCruz et al. // Clinical and Developmental Immunologyю. – 2013. - Vol.
2013. – 15 p.106. Jelcic, I. Memory B Cells Activate Brain-Homing, Autoreactive CD4+TCells in Multiple Sclerosis / I. Jelcic, F. Al Nimer, J. Wang et al. // Cell. – 2018. – Vol.175, № 1. – P. 85–123.107. Kaer, L.V. Natural killer T cells in multiple sclerosis and its animal model,experimental autoimmune encephalomyelitis / L.V. Kaer, L.
Wu, V.V. Parekh //Immunology. – 2015. – Vol. 146. – P. 1–10.108. Karni, A. Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells inSecondary Progressive Multiple Sclerosis Are Activated and Drive a ProinflammatoryImmune Response / A. Karni, M. Abraham, A. Monsonego et al. // The Journal ofImmunology. – 2006. – Vol.
177. – P. 4196-4202.109. Knier, B. Association of Retinal Architecture, Intrathecal Immunity, andClinical Course in Multiple Sclerosis / B. Knier, G. Leppenetier, C. Wetzlmair et al. //JAMA Neurology. – 2017. – Vol. 74, №7. – P. 847-856.110.
Kuhle, J. Conversion from clinically isolated syndrome to multiple sclerosis:A large multicentre study / J. Kuhle, G. Disanto, R. Dobson et al. // Multiple SclerosisJournal. – 2015. – Vol. 21, № 8. – P. 1013–1024.132111. Lagumersindez‑Denis, N. Differential contribution of immune effectormechanisms to cortical demyelination in multiple sclerosis / N. Lagumersindez‑Denis,C. Wrzos, M. Mack // Acta Neuropathol. – 2017. – Vol. 134, № 1. – P. 15–34.112. La Rocca, C. Immunometabolic profiling of T cells from patients withrelapsing-remittingmultiplesclerosisrevealsanimpairmentinglycolysisandmitochondrial respiration / C.
La Rocca, F. Carbone, V. De Rosa et al. //Metabolism Clinical and Experimental. – 2017. – Vol. 77. – P. 39–46.113. Lee, D.-H. Diagnostic value of the 2017 McDonald criteria in patients with afirst demyelinating event suggestive of relapsing remitting multiple sclerosis / D.-H.Lee, M. Peschke, K.S.
Utz, R.A. Linker // European Journal of Neurology. – 2018. doi: 10.1111/ene.13853.114. Legroux, L. Multiple Sclerosis and T Lymphocytes: An Entangled Story / L.Legroux, N. Arbour // J Neuroimmune Pharmacol. – 2015. – Vol. 10, № 4. – P. 528–546.115. Lehmann-Horn, K. Deciphering the Role of B Cells in Multiple Sclerosis—Towards Specific Targeting of Pathogenic Function / K. Lehmann-Horn, S. Kinzel,M.S. Weber // International Journal of Molecular Sciences. – 2017. Vol. 18, № 10. – P.2048 – 2065.116. Li, R. Reassessing B cell contributions in multiple sclerosis / R.
Li, K.R.Patterson, A. Bar-Or // Nature Immunology. – 2018. – Vol. 19, №7. – P. 696–707.117. Li, Y. CD6 as a potential target for treating multiple sclerosis / Y. Li, N.G.Singer, J.Whitbred et al. // Proceedings of the National Academy of Sciences. – 2017.Vol. 114, № 10. – P. 2687-2692.118. Libbey, J.E. Role of Pathogens in Multiple Sclerosis / J.E. Libbey, M.F.Cusick, R.S. Fujinami // International Reviews of Immunology. – 2013. – Vol.
EarlyOnline. – P. 1–18.119. Lisak, R.P. Neurodegeneration in multiple sclerosis: defining the problem /R.P. Lisak // Neurology. – 2007. – Vol. 68, № 3. – P. 5–12.133120. Machado-Santos, J. The compartmentalized inflammatoryresponse in themultiple sclerosis brain iscomposed of tissue-resident CD8 +T lymphocytes and B cells/ J. Machado-Santos, E. Saji, A.R. Tro s̈ cher et al. // Brain: A Journal of Neurology. –2018. – Vol.
141. – P. 2066–2082.121. Magliozzi, R. Meningeal B-cell follicles in secondary progressive multiplesclerosis associate with early onset of disease and severe cortical pathology / R.Magliozzi, O. Howell, A. Vora et al. // Brain. – 2007. – Vol. 130. – P. 1089-1104.122. Martin, R.
Current multiple sclerosis treatments have improved ourunderstanding of MS autoimmune pathogenesis / R. Martin, M. Sospedra, M. Rosito, B.Engelhardt // Eur. J. Immunol. - 2016. – Vol. 46. – P. 2078–2090.123. Matsuia, M. Immunomonitoring measures in relapsing-remitting multiplesclerosis / M. Matsuia, Sh. Arayaa, H.-Y. Wanga et al. // Journal of Neuroimmunology.– 2004. – Vol. 148.
– P. 192–199.124. MSIF. Atlas of MS 2013: Mapping Multiple Sclerosis Around The World /MultipleSclerosisInternationalFederation.-2013.–Режимдоступа:http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf.125. Montalban, X. ECTRIMS/EAN Guideline on the pharmacological treatmentof people with multiple sclerosis / X. Montalban, R. Gold, A.J Thompson et al. //Multiple Sclerosis Journal.
– 2018. – Vol. 24, № 2. – P. 96-120.126. Mowry, E.M. Demyelinating events in early multiple sclerosis have inherentseverity and recovery / E.M. Mowry, M. Pesic, B. Grimes et al. // Neurology. – 2009. –Vol. 72. – P. 602–608.127. Porrini, A.M. Memory and naive CD4+ lymphocytes in multiple sclerosis /A.M. Porrini, D. Gambi, G. Malatesta // J Neurol. – 1992. – Vol.
239. P. 437-440.128. Prinz, M. Microglia and brain macrophages in the molecular age: fromorigin to neuropsychiatric disease / M. Prinz, J.Priller // Nature Reviews Neuroscience.– 2014. – Vol. 15, № 5. – P. 300–312.129. Prolonged dynamic clinico-immunological observation of 85 patients withdefinite multiple sclerosis: first steps towards monitoring process activity / E.I. Gusev,T.L. Demina, A.N. Boiko, B. V. Pinegin // J Neurol. – 1994. – Vol. 241. - P. 500-510.134130. Rose, L.M. Selective loss of a subset of T helper cells in active multiplesclerosis (two-color cell sorter analysis/T helper subpopulations/neuroimmunologicdisease) / L.M. Rose, A.H. Ginsberg, T.L.
Rothstein et al. // Proc. Nati. Acad. Sci. USA.– 1985. - Vol. 82, №21. - P. 7389-7393.131. Severson, C. T-cells in multiple sclerosis / C. Severson, D.A. Hafler //Results probl cell differ. – 2010. – Vol. 51. – P. 75–98.132. Sinha, S. Immune regulation of multiple sclerosis by CD8+ T cells / S.Sinha, F.R. Itani, N.J. Karandikar // Immunologic Research. – 2014. – Vol. 59, № 1–3.– P.
254–265.133. Symington, G.R. A “profile” of immune responsiveness in multiple sclerosis/ G.R. Symington, I.R. Mackay, S. Whittingham et al. // Clin. exp. Immunol. – 1978. –Vol. 31. – P. 141-149.134. Yin, J. The Role of Microglia and Macrophages in CNS Homeostasis,Autoimmunity, and Cancer / J. Yin, K.L. Valin, M.L. Dixon, J.W. Leavenworth //Journal of Immunology Research. – 2017. - Vol. 2017. – 12 p.135.
Ulivieri, C. Regulation of T Cell Activation and Differentiation byExtracellular Vesicles and Their Pathogenic Role in Systemic Lupus Erythematosus andMultiple Sclerosis / C. Ulivieri, C.T. Baldari // Molecules. – 2017. – Vol. 22, №2. – P.225-238.136. Weber, M.S. Cooperation of B Cells and T Cells in the Pathogenesis ofMultiple Sclerosis / M.S. Weber, B.
Hemmer // Molecular Basis of Multiple Sclerosis. Springer-Verlag Berlin Heidelberg, 2009 – P. 115-126.137. Weiner, H.L. A shift from adaptive to innate immunity: a potentialmechanism of disease progression in multiple sclerosis / H.L. Weiner // J Neurol.
–2008. – Vol. 255, № 1. – P. 3–11.138. Wekerle, H. T-Cell Autoimmunity in the Central Nervous System / H.Wekerle // Intervirology. – 1993. – Vol. 35. – P. 95-100.139. Yshii, L.M. Inflammatory CNS disease caused by immune checkpointinhibitors: status and perspectives / L.M. Yshii, R. Hohlfeld, R.S. Liblau // ClinicalRheumatology. – 2018. – Vol. 37, № 4. – P.
1107–1110.135ПРИЛОЖЕНИЕ 1Оценка функциональных систем по Куртцке (в баллах)136137138Расширенная шкала инвалидизации по Куртцке (шкала EDSS)139ПРИЛОЖЕНИЕ 2Оценка неврологического статуса по шкале Scripps140ПРИЛОЖЕНИЕ 3Диагностические критерии рассеянного склероза по Мак Дональду.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
